Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now
featured
Published in Oncology and
1 other channel

Journal Scan / Research · October 14, 2021

Apalutamide Plus Abiraterone Acetate and Prednisone in Metastatic Castration-Resistant Prostate Cancer

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

The Lancet Oncology
Apalutamide Plus Abiraterone Acetate and Prednisone Versus Placebo Plus Abiraterone and Prednisone in Metastatic Castration-Resistant Prostate Cancer (ACIS): A Randomised, Placebo-Controlled, Double-Blind, Multinational, Phase 3 Study
Lancet Oncol 2021 Sep 30;[EPub Ahead of Print], F Saad, E Efstathiou, G Attard, TW Flaig, F Franke, OB Goodman, S Oudard, T Steuber, H Suzuki, D Wu, K Yeruva, P De Porre, S Brookman-May, S Li, J Li, S Thomas, KB Bevans, SD Mundle, SA McCarthy, DE Rathkopf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated